학술논문
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes
Document Type
article
Author
Rubinstein, Samuel M; Bhutani, Divaya; Lynch, Ryan C; Hsu, Chih-Yuan; Shyr, Yu; Advani, Shailesh; Mesa, Ruben A; Mishra, Sanjay; Mundt, Daniel P; Shah, Dimpy P; Sica, R Alejandro; Stockerl-Goldstein, Keith E; Stratton, Catherine; Weiss, Matthias; Beeghly-Fadiel, Alicia; Accordino, Melissa; Assouline, Sarit E; Awosika, Joy; Bakouny, Ziad; Bashir, Babar; Berg, Stephanie; Bilen, Mehmet Asim; Castellano, Cecilia A; Cogan, Jacob C; Kc, Devendra; Friese, Christopher R; Gupta, Shilpa; Hausrath, Daniel; Hwang, Clara; Johnson, Nathalie A; Joshi, Monika; Kasi, Anup; Klein, Elizabeth J; Koshkin, Vadim S; Kuderer, Nicole M; Kwon, Daniel H; Labaki, Chris; Latif, Tahir; Lau, Eric; Li, Xuanyi; Lyman, Gary H; McKay, Rana R; Nagaraj, Gayathri; Nizam, Amanda; Nonato, Taylor K; Olszewski, Adam J; Polimera, Hyma V; Portuguese, Andrew J; Puc, Matthew M; Razavi, Pedram; Rosovski, Rachel; Schmidt, Andrew; Shah, Sumit A; Shastri, Aditi; Su, Christopher; Torka, Pallawi; Wise-Draper, Trisha M; Zubiri, Leyre; Warner, Jeremy L; Thompson, Michael A
Source
Blood Cancer Discovery. 3(3)
Subject
Language
Abstract
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.